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ABSTRACT
Targeted therapeutic agents, such as inhibitors of epithelial growth factor
receptor (EGFR), have transformed the management of non-small cell lung cancer
(NSCLC) patients. MET-amplified NSCLC cells display resistance to EGFR-targeting
agents, but are addicted to MET signaling for survival and proliferation and are
sensitive to MET inhibition. However, responsive cancer cells invariably develop
resistance to MET-targeted treatment.
The tumor microenvironment plays a major role in resistance to anticancer
therapy. We demonstrated that fibroblasts block the response of MET-amplified NSCLC
cells to the MET kinase inhibitor, JNJ38877605 in an HGF-dependent manner. Thus,
MET-amplified NSCLC cells become addicted to HGF upon pharmacological inhibition
of MET. HGF restored phosphorylation of MET, EGFR and RON, and maintained prosurvival AKT and ERK signaling in MET-inhibited cells.
We developed a small molecule inhibitor of pro-HGF activation, SRI31215,
which acts as a triplex inhibitor of the pro-HGF activating proteases matriptase,
hepsin and HGF activator (HGFA). SRI31215 blocked crosstalk between tumor cells
and fibroblasts and overcame fibroblast-mediated resistance to MET inhibition by
preventing fibroblast-mediated reactivation of AKT and ERK signaling. Structurally
unrelated triplex inhibitors of matriptase, hepsin and HGFA that we developed in
parallel showed similar biological activity.
Our data suggest that simultaneous inhibition of HGF and MET is required to
overcome resistance to MET inhibitors in MET-amplified NSCLC cells. This provides
a rationale for the development of novel combination therapeutic strategies for the
treatment of NSCLC patients with MET amplification.

mutations [1–3]. However, innate or acquired resistance
limits the efficacy of kinase inhibitors. The presence of
KRas, BRaf and ERBB2 mutations predicts primary
resistance to EGFR inhibitors [4, 5]. Acquired resistance
to EGFR inhibitors has been associated most frequently
with selection for secondary EGFR mutations, such as
T790M in exon 20 [6, 7] and with MET amplification [8].
Second and third generation EGFR inhibitors have been
developed and novel combination of these inhibitors with

INTRODUCTION
Lung cancer remains a leading cause of cancerrelated deaths worldwide. Oncogenic EGFR activation,
commonly observed in non-small cell lung cancer
(NSCLC), drives cell proliferation and survival. Indeed,
EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib have become an important therapeutic
modality for the treatment of NSCLC patients with EGFR
www.impactjournals.com/oncotarget
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other therapies have been tested to overcome therapeutic
resistance [9]. Additionally, drugs that target MET are in
clinical trials to overcome MET-amplification-mediated
resistance to EGFR inhibitors [10].
MET amplifications have been found in ~20% of
NSCLC patients with acquired resistance to gefitinib
or erlotinib [8, 11]. MET-amplified lung cancer cells
do not respond to EGFR inhibitors [12], but are highly
sensitive to MET inhibition [13, 14]. Several MET kinase
inhibitors have been evaluated in clinical trials [15],
however acquired resistance remains a serious limitation
of these drugs. Although the mechanisms of resistance
to MET targeting drugs are not well understood, it has
been shown that a switch to EGFR dependency can
underlie the resistance to MET kinase inhibitors. Thus,
one approach to optimize the anticancer activity and to
prevent the growth of resistant clones in MET-amplified
lung cancer cells is the combined therapy with MET
and EGFR inhibitors [16, 17]. However, lung cancer
cells with amplified MET and overexpressed EGFR
frequently show limited response to combined treatment
[16, 18], underscoring the necessity to identify additional
mechanism of resistance.
In addition to cell-autonomous mechanisms of
resistance, factors in the tumor microenvironment have
been shown to block the response to therapy [19, 20].
Stroma-induced resistance to targeted therapy is frequently
mediated by hepatocyte growth factor (HGF)-induced
activation of MET [19–21]. HGF activates pro-survival
signaling and promotes epithelial-mesenchymal transition
of cancer cells, hindering the response to therapy. HGF
has been shown to block the response of lung cancer cells
to EGFR targeting drugs [22, 23] and increased levels of
serum HGF predict poor progression-free survival and
overall survival in NSCLC patients treated with EGFR
inhibitors [24, 25]. Surprisingly, it has recently been
shown that MET-amplified lung cancer cells become
dependent on HGF for survival upon pharmacologic MET
inhibition [26]. This indicates that both HGF and MET
need to be targeted in MET-amplified NSCLC to prevent
or to delay the onset of resistance.
Neutralizing anti-HGF antibodies that are being
tested, alone or in combination with other therapies,
appear to be well tolerated in clinical trials [27, 28].
They have shown encouraging results, yielding partial
responses in cancer patients. However, there are
currently no small molecule HGF inhibitors available
for clinical trials. We developed and characterized two
distinct series of low molecular weight inhibitors of
HGF, which act as inhibitors of pro-HGF activation
[29, 30].
HGF is secreted as a single chain inactive precursor
called pro-HGF. Proteolytic conversion of pro-HGF to the
heterodimeric active HGF is required to trigger liganddependent MET signaling. This is achieved by one of the
trypsin-like serine proteases, matriptase, hepsin or HGF
www.impactjournals.com/oncotarget

activator (HGFA), which are expressed by tumor cells
[31]. A proteolytically inert mutant form of pro-HGF
(uncleavable-HGF) or a truncated form of HGF that lacks
the β-chain (NK4) displayed a competitive antagonism
with HGF for MET binding. Both mutants suppressed
proliferation, migration, and invasion of cancer cells and
inhibited tumor growth and metastasis in vivo [32–35].
We demonstrated that triplex inhibitors of matriptase,
hepsin and HGFA prevent activation of pro-HGF and
inhibit HGF/MET signaling. SRI31215, a novel inhibitor
of pro-HGF activation, blocked signaling between tumorpromoting fibroblasts and colon cancer cells and overcame
fibroblast-mediated resistance to EGFR inhibitors in colon
cancer cells [30, 36].
In this study, we established that recombinant HGF or
HGF-producing fibroblasts protect MET-amplified NSCLC
cells from MET-targeting therapy by maintaining AKT and
ERK signaling in MET-inhibited cells. We demonstrated
that novel inhibitors of HGF activation overcome fibroblastmediated resistance to MET inhibition in MET-amplified
lung cancer cells. This highlights the need to include agents
blocking the biological activity of HGF, such as inhibitors
of pro-HGF activation, into therapeutic regimens for METamplified NSCLC patients.

RESULTS
HGF rescues MET-amplified lung cancer cells
from MET tyrosine kinase inhibition
Whereas MET-amplified lung cancer cells do not
respond to EGFR inhibition, their growth is strongly
inhibited by MET tyrosine kinase inhibitors, confirming
that these cells are addicted to MET signaling [13, 14].
Accordingly, the selective MET tyrosine kinase inhibitor,
JNJ38877605, inhibits the viability of two MET-amplified
NSCLC cell lines, EBC-1 and H1993 (Figure 1A and 1B).
Inhibition of HGF using an HGF-specific neutralizing
antibody had no impact on the viability of EBC-1 or
H1993 cells (Figure 1A and 1B), confirming that MET
amplification triggers ligand-independent MET signaling.
We showed that JNJ38877605 inhibits the viability of
EBC-1 cells in a dose- and time-dependent manner
(Supplementary Figure 1A and 1B). In contrast, A549 cells,
which do not harbor amplified MET, did not respond to the
growth-inhibitory effect of JNJ38877605 (Figure 1C). This
demonstrates that MET-amplified lung cancer cells display
selective sensitivity to MET kinase inhibition.
HGF has been shown to mediate resistance to several
targeted therapeutic agents such as inhibitors of EGFR,
BRaf and HER2 [20, 37]. Here we show that HGF also
blocks the response to JNJ38877605, a specific MET
kinase inhibitor, in MET-amplified EBC-1 and H1993
cells (Figure 1D-1F). HGF increased the survival of METinhibited cells in a dose-dependent manner (Supplementary
Figure 1C). Pro-HGF, the inactive precursor of HGF, was
63015
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as potent as HGF in protecting EBC-1 and H1993 cells
from JNJ38877605-induced cell death (Figure 1D-1F),
confirming that these cell lines express enzyme(s) that can
activate pro-HGF into its mature form.
These data indicated that MET-amplified NSCLC
cells rely on HGF for survival upon pharmacological
inhibition of MET. We have shown earlier that SRI31215,
a triplex inhibitor of matriptase, hepsin and HGFA, (Figure
2), inhibits pro-HGF activation [36]. Here we show that
SRI31215 blocks the pro-survival activity of pro-HGF in
EBC-1 and H1993 cells (Figure 1D and 1E). Consistent
with its mode of action, SRI31215 does not impact the
pro-survival activity of mature HGF (Figure 1D) [36].
The levels of matriptase and hepsin, two of
the pro-HGF converting enzymes, are significantly
elevated in lung cancer compared to normal lung tissue
(Supplementary Figure 2). Moreover, the levels of HGF
are increased in lung cancer tissue compared to normal
lung mucosa (Supplementary Figure 2), suggesting that
inhibition of pro-HGF activation is a valid approach to
inhibit HGF/MET signaling.

main source of pro-HGF in the tumor microenvironment,
therefore we tested whether inhibitors of pro-HGF activation
can overcome fibroblast–mediated resistance to METtargeted therapy. These experiments were performed in the
absence of serum, which contains enzymes that can cleave
and activate pro-HGF.
Consistent with our finding that HGF and pro-HGF
block the activity of JNJ38877605 (Figure 1D and 1E),
conditioned medium from WI38 lung fibroblasts which
produce pro-HGF (Supplementary Figure 3A) rescued
EBC-1 and H1993 cells from JNJ38877605-induced cell
death (Figure 3A and 3B). We showed that fibroblasts
with silenced HGF (Supplementary Figure 3A) failed
to inhibit the response of EBC-1 cells to JNJ38877605
(Figure 3A). Accordingly, HGF neutralizing antibodies
blocked the ability of fibroblasts to protect EBC-1 cells
from JNJ38877605-induced cell death (Figure 3A).
These experiments established that fibroblasts inhibit
JNJ38877605-induced cell death through HGF. Consistent
with published data [17], HGF or fibroblasts did not
further stimulate MET signaling (Supplementary Figure
3B) or promote the growth of MET-amplified EBC-1
(Figure 3A).
Like HGF neutralizing antibodies, SRI31215
blocked the ability of fibroblasts to rescue EBC-1 and
H1993 cells from JNJ38877605-induced cell death (Figure
3A and 3B). Accordingly, the substrate-based peptide
inhibitors of matriptase, hepsin and HGFA, ZFH7054,
ZFH7074 and ZFH7116 (Figure 2) restored the sensitivity

Inhibition of pro-HGF activation overcomes
fibroblast-mediated resistance to MET kinase
inhibition
HGF is a key growth factor in the tumor microenvironment that inhibits the response of cancer cells to
targeted therapy [20]. Cancer-associated fibroblasts are the

Figure 1: HGF rescues MET-amplified lung cancer cells from MET inhibition. EBC-1 (A) and H1993 (B) MET-amplified

lung cancer cells, and A549 cells (C) which do not have amplified MET were treated with JNJ38877605 (JNJ) (25 nM) or HGF neutralizing
antibody (α-HGF Ab). Cell viability was determined after 72 h by CellTiter Glo®. (D and E) EBC-1 and H1993 cells were treated
with JNJ38877605 (25 nM), HGF (100 nM) or pro-HGF (100 nM) as indicated. Cell viability was determined by CellTiter Glo®. (F)
Representative images of EBC-1 cells treated with JNJ38877605 alone or with HGF or pro-HGF after 72 h of treatment.
www.impactjournals.com/oncotarget
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of EBC-1 cells to JNJ38877605 in the presence of
fibroblasts and overcame the ability of pro-HGF to rescue
EBC-1 cells from MET inhibition (Supplementary Figure
3C). Treatment of EBC-1 cells with SRI31215, ZFH7054,
ZFH7074 or ZFH7116 alone did not have any impact on
the viability of EBC-1 cells (Supplementary Figure 3D),
confirming that these compounds do not target cancer cells

directly, but inhibit the crosstalk between cancer cells and
fibroblasts.
To understand the mechanism whereby HGF elicits
resistance to JNJ38877605, EBC-1 cells were treated with
JNJ38877605 alone or in the presence of recombinant HGF
or fibroblasts and SRI31215. As expected, JNJ38877605
inhibited the expression of p-MET, p-EGFR, p-Gab1, p-ERK

Figure 2: Molecular structure and activity of SRI31215 (A) and peptide inhibitors of pro-HGF activation, ZFH7054,
ZFH7074 and ZFH7116 (B). The IC50 values for matriptase, hepsin and HGFA are indicated in bold.

Figure 3: Inhibition of pro-HGF activation overcomes fibroblast-mediated resistance to MET tyrosine kinase inhibition.

(A) EBC-1 cells were treated with JNJ38877605 (25 nM) alone or in the presence of conditioned medium (CM) from WI38 fibroblasts
(FIB). CM was also prepared from fibroblasts with silenced HGF (HGF-/- FIB), or from fibroblasts cultured with HGF neutralizing antibody
(α-HGF Ab) or SRI31215 (10 μM) as indicated. Cell viability was determined by CellTiter Glo®72 h after treatment. (B) H1993 cells were
treated with JNJ38877605 (25 nM), fibroblast CM (FIB) and SRI31215 (10 μM) as indicated and cell viability was determined after 72 h.
(C) Serum-starved EBC-1 cells were treated with JNJ38877605, recombinant HGF (100 nM), FIB and SRI31215 (10 μM) as indicated for
6 hours. Cell lysates were analyzed by immunoblotting for phospho- and total MET, EGFR, Gab1, AKT and ERK 1/2. *, p < 0.05 compared
to JNJ/FIB.
www.impactjournals.com/oncotarget
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1/2 and p-AKT (Figure 3C). We demonstrated that HGF or
pro-HGF-producing fibroblasts restored phosphorylation
of MET, EGFR and Gab1 in JNJ38877605-treated EBC-1
cells. Accordingly, HGF or fibroblasts reactivated ERK1/2
and AKT signaling upon pharmacological MET inhibition
by JNJ38877605. Importantly, SRI31215 blocked fibroblastinduced MET and EGFR signaling and AKT and ERK
activation in MET-inhibited cells (Figure 3C), consistent
with its ability to sensitize EBC-1 and H1993 cells to
JNJ38877605 (Figure 3A and 3B). The levels of total MET,
EGFR, Gab1 and AKT were not altered by the treatments
(Figure 3C). Treatment of cells with HGF, fibroblasts or
SRI31215 alone did not alter the expression or the activity
of MET, EGFR, Gab1 or AKT (Supplementary Figure 3B).
Collectively, our data show that fibroblasts elicit
resistance to MET-targeted therapy through HGF in METamplified lung cancer cells. We showed that HGF is sufficient
to sustain MET and EGFR signaling and downstream
activation of ERK and AKT upon MET inhibition. Inhibitors
of pro-HGF that we developed blocked the pro-survival
activity of fibroblasts, indicating that dual inhibition of MET
and HGF is required to overcome resistance to MET-targeted
therapy in MET-amplified NSCLC.

leads to enhanced migration of cancer cells [38].
Indeed, the migration of MET-amplified EBC-1 cells
was completely inhibited by the MET tyrosine kinase
inhibitor, JNJ38877605 (Figure 4). The inhibitory effect
of JNJ38877605 on the migration of EBC-1 cells was
prevented by either recombinant HGF or by WI38 lung
fibroblasts (Figure 4). This result established that METamplified NSCLC cells become dependent on HGF not
only for survival, but also for migration when MET is
inhibited.
We have shown previously that SRI31215 impedes
crosstalk between colon cancer cells and fibroblasts and
thus inhibits the tumor-promoting activities of fibroblasts
in colon cancer [36]. Here we demonstrate that SRI31215
blocks the ability of fibroblasts to restore the migration
of MET-inhibited EBC-1 cells (Figure 4). The peptide
inhibitors of pro-HGF activation, ZFH7054, ZFH7074
and ZFH7116 (Figure 2) which target the three pro-HGF
activating enzymes [29], also blocked fibroblast-mediated
migration of MET-inhibited EBC-1 cells (Supplementary
Figure 4). Treatment of cancer cells with inhibitors of proHGF activation alone had no impact on the migration of
EBC-1 cells (Figure 4 and Supplementary Figure 4).
Thus, while HGF (or fibroblasts) do not further
stimulate MET signaling (Supplementary Figures 3B
and 5A) or promote the viability (Figure 3) in METamplified cancer cells, our results established that METamplified NSCLC cells become addicted to HGF upon
pharmacological MET inhibition. HGF-producing
fibroblasts promote the survival and migration of

HGF supports the migration of MET-amplified
EBC-1 lung cancer cells upon MET tyrosine
kinase inhibition
MET activation promotes growth, survival and
stimulates epithelial-mesenchymal transition which

Figure 4: HGF upholds the migration of MET-addicted EBC-1 lung cancer cells upon MET tyrosine kinase inhibition.

Migration of EBC-1 cells was assessed by a transwell migration assay. EBC-1 cells were treated with JNJ38877605 (25 nM) in the absence
or presence of recombinant HGF or conditioned medium from fibroblasts (FIB) and SRI31215 (10 μM) for 24 h. (A) Representative images
of stained cells that migrated across the polycarbonate membrane. (B) Relative migration of cells was determined by the optical density
(OD) of stained cells at 560 nm.*, p < 0.05 compared to JNJ/FIB.
www.impactjournals.com/oncotarget
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MET-amplified lung cancer cells when MET is inhibited.
We demonstrated that novel inhibitors of pro-HGF
processing block crosstalk between tumor cells and
fibroblasts and thus restrain the tumor-promoting activity
of fibroblasts.

increased phosphorylation of MET-related receptor RON,
HER2, HER3 and RYK, which is likely to contribute to
the pro-survival activity of HGF (Figure 5B).

HGF-induced signaling in MET-inhibited cells

The tumor-microenvironment plays a major
role in resistance to targeted therapy. In this study we
demonstrated that HGF, commonly produced by cancerassociated fibroblasts, confers resistance to MET kinase
inhibitors in MET-amplified NSCLC cells. We showed
that a novel inhibitor of pro-HGF activation, SRI31215,
blocks the crosstalk between cancer cells and fibroblasts
and overcomes resistance to anti-MET therapy in METamplified NSCLC cells.
The availability of targeted therapeutic options,
such as EGFR inhibitors, has improved the management
of patients with EGFR mutant NSCLC. However, only a
fraction of patients shows a good clinical response to EGFR
inhibitors and virtually all patients develop resistance to
therapy [41–43]. Acquired resistance to EGFR inhibitors
has been associated most frequently with selection for
secondary EGFR mutations, such as T790M in exon 20
[6, 7] and MET amplifications [8]. MET-amplified lung
cancers, which display ligand-independent MET activation,
are addicted to MET signaling and are extremely sensitive
to MET inhibition [13]. Nevertheless, acquired resistance
to MET kinase inhibitors remains a major limitation of
these drugs. In some cases, a switch to EGFR dependency
has been shown to underlie the resistance to MET kinase
inhibitors [16, 17]. However, some lung cancer cells with
amplified MET and overexpressed EGFR fail to respond
to combined treatment with EGFR and MET inhibitors
or develop resistance to dual EGFR/MET inhibition
[44]. Indeed, resistance to dual EGFR/MET inhibition
has recently been reported in a MET-amplified NSCLC
patient [45].
The tumor microenvironment has been shown to
elicit resistance to therapy. HGF, which is commonly
overexpressed in the tumor microenvironment, is a
frequent source of resistance to targeted therapy [19–21].
HGF activates MET, expressed on tumor cells, and drives
resistance to EGFR-targeted therapy by triggering ERK
and PI3K/AKT pro-survival signaling and by promoting
epithelial-mesenchymal transition [20]. Elevated levels
of circulating HGF are associated with a mesenchymal
tumor type, poor patient prognosis and resistance to
EGFR inhibitors in lung cancer patients [11, 25]. Notably,
EGFR inhibitors have been shown to elevate plasma levels
of HGF in NSCLC patients [46], which may be due to
therapy-induced recruitment of fibroblasts. HGF is also
induced in airway epithelium by smoking [47], by far the
biggest cause of lung cancer.
Here we demonstrated that HGF also drives
resistance to anti-MET therapy in MET-amplified lung
cancer cells (Figure 1 and Figure 3). Thus, MET-amplified

DISCUSSION

To understand how HGF signals in MET-amplified
lung cancer cells when MET kinase activity is inhibited,
we used the Proteome Profiler Human Phospho-RTK array
(R&D Systems) to investigate the phosphorylation profiles
of 49 different receptor tyrosine kinases. Additionally, we
used Phospho-Kinase Array (R&D Systems) containing 46
kinases and their substrates.
Inhibition of MET kinase by JNJ38877605
blocked MET phosphorylation, however we showed
that JNJ38877605 also significantly reduced
phosphorylation of EGFR, RON (Figure 5A), AXL and
RET (Supplementary Figure 5A). This suggests that MET
cross-phosphorylates these RTKs in MET-amplified EBC1 cells. Indeed, MET interacts with several other receptor
tyrosine kinases (RTKs) and MET heterodimers with
EGFR, RON, HER2 and HER3 have been found abundant
in MET-amplified cancer cells [39].
HGF restored phosphorylation of MET, EGFR
and RON in MET-inhibited EBC-1 cells (Figure
5A, Supplementary Figure 5D), but did not rescue
phosphorylation of AXL or RET (Supplementary Figure
5A) in JNJ38877605-treated cells. The array analysis
confirmed that HGF restored activation of ERK and AKT
in MET-inhibited cells (Supplementary Figure 5B). In
addition, we found that WNK1, a prosurvival kinase that
signals through ERK5 and Wnt [40], is highly activated in
MET-amplified EBC-1 cells (Supplementary Figure 5C).
Inhibition of MET kinase by JNJ38877605 significantly
reduced phosphorylation of WNK1 in EBC-1 cells and
HGF restored its activity in MET inhibited cells. In contrast,
the levels of HSP60 were not restored by HGF in METinhibited cells (Supplementary Figure 5C). This indicates
that novel mechanisms, such as WNK1 activation, may
contribute to prosurvival activity of HGF in MET-amplified
NSCLC cells and maintain the tumor-promoting crosstalk
between tumor cells and cancer- associated fibroblasts. The
potential role of WNK1 in HGF signaling and in HGF/
fibroblast-dependent resistance to targeted therapy needs to
be confirmed in other NSCLC cell lines.
How does HGF signal in MET-inhibited cells?
It is possible that due to MET overexpression in METamplified cells there is always some residual MET in
MET- inhibited cells, which responds to HGF stimulation.
Indeed, we showed that HGF reactivates MET in
JNJ38877605-treated cells (Figure 3 and Figure 5).
However, we cannot exclude the possibility that HGF, at
least in part, promotes survival of MET- amplified cells
in a MET-independent manner. In fact, HGF stimulation
www.impactjournals.com/oncotarget
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NSCLC cells become addicted to HGF upon MET
inhibition. HGF reactivates MET, EGFR and RON
phosphorylation and restores AKT, ERK and WNK1
signaling upon MET inhibition (Figure 3, Figure 5,
Supplementary Figure 5), promoting the survival of METinhibited cancer cells. Thus, simultaneous inhibition of
HGF and MET may be required to prevent resistance to
targeted therapy in MET-amplified NSCLC cells.
Neutralizing anti-HGF antibodies that are being
tested, alone or in combination with other therapies, appear
to be well tolerated. They have shown encouraging results,
yielding partial response in cancer patients [28, 48–51].
There are currently no known small molecule inhibitors of
HGF available, which have several advantages compared
to therapeutic antibodies [52]. We developed SRI31215,
a novel small molecule inhibitor of pro-HGF activation,
which is the rate-limiting step in HGF/MET signaling
[30]. HGF is synthesized and secreted by tumors or, more
commonly, by stromal cells as an inactive precursor, proHGF. SRI31215 is a triplex inhibitor of the three serine
proteases, matriptase, hepsin and HGFA, each of them
being sufficient for the processing of pro-HGF into the
biologically active ligand [31]. Structurally distinct
triplex inhibitors of matriptase, hepsin and HGFA that we
developed in parallel (Figure 2) exert similar biological
activity as SRI31215 (Supplementary Figures 3 and 4).
SRI31215 and the peptide inhibitors mimic the activity
of Hepatocyte Growth Factor Activator Inhibitors (HAI1/2), which act as endogenous inhibitors of pro-HGF
activation, and inhibit matriptase, hepsin and HGFA [31,
53]. While HGF-activating enzymes are upregulated in
lung cancer (Supplementary Figure 2), the levels of HAI1/2 are commonly reduced in cancer tissue, resulting in

increased activation of HGF. Reduced expression of the
HAIs is associated with advanced stage disease and poor
prognosis in many cancers [54–60].
We demonstrated previously that SRI31215
effectively inhibits HGF-dependent MET activation,
proliferation, epithelial-mesenchymal transition and
migration of cancer cells and overcomes fibroblastmediated resistance to EGFR inhibitors in colon cancer
cells [36]. Here we established that SRI31215, and
peptide-based inhibitors of pro-HGF activation, block the
tumor-promoting activity of fibroblasts and overcome the
resistance of MET-amplified lung cancer cells to anti-MET
therapy (Figures 3 and 4). Our preliminary data indicate
that SRI31215 also overcomes resistance to double MET/
EGFR inhibition (data not shown).
Several MET kinase inhibitors have been developed
and have entered clinical trials. In preclinical studies
cancer cells rapidly develop resistance to MET kinase
inhibitors, which will probably translate to resistance in
patients. It has been demonstrated that discontinuation of
MET tyrosine kinase inhibitors results in increased and
prolonged MET activation, coupled to enhanced tumor
growth in vitro and in vivo [61], suggesting that MET
inhibitors will need to be combined with other therapies
[62].
The mechanisms whereby cancer cells develop
resistance to MET kinase inhibitors are not well
understood. Recently, a lung adenocarcinoma patient
with MET amplification developed resistance to dual
anti-EGFR/MET therapy due to an acquired METD1228V
mutation [45]. We demonstrated that HGF, commonly
overexpressed in the tumor microenvironment, confers
resistance to MET- targeted therapy in MET-amplified

Figure 5: HGF-induced signaling in MET inhibited NSCLC cells. EBC-1 cells were treated with JNJ38877605 (25 nM) or HGF

(100 nM) alone, or with a combination of JNJ38877605 and HGF for 6 hours. Cell lysates were prepared and subjected to antibody-based
human phospho-receptor tyrosine kinase (RTK) array as described in methods to analyze the phosphorylation profiles of receptor tyrosine
kinases. *, p < 0.05 compared to JNJ38877605 (JNJ); #, p < 0.05 compared to CTRL.
www.impactjournals.com/oncotarget
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NSCLC cells. Thus, small molecule inhibitors of proHGF activation such as those described herein, offer
a new approach to restore sensitivity to MET or MET/
EGFR inhibition in MET-amplified NSCLC patients.
Plasma levels of HGF can serve as a biomarker to select
lung cancer patients that would benefit from drugs that
counteract the biological activity of HGF.
In summary, our data underscore a key role of the
tumor microenvironment in acquired resistance to MET
kinase inhibitors in MET-amplified NSCLC cells. We
demonstrated that MET-amplified NSCLC cells become
addicted to HGF under pharmacological MET inhibition.
Because HGF is frequently overexpressed in the tumor
microenvironment, our work highlights the need to include
inhibitors of biological activity of HGF into therapeutic
regimen in MET-amplified NSCLC patients.

to the manufacturer’s instructions. EBC-1 cells were
seeded in transwells (8 μM pore size inserts) at a density
of 7.5X104 cells/well in serum-free media. Transwells
were placed in wells (24-well format) containing 10%
serum-containing media and incubated for 24h. Cells that
migrated were stained for 10 minutes at room temperature,
transferred to wells containing 200 μl of extraction buffer
and incubated for 10 minutes on a shaker. The optical
density (OD) of stained cells was measured at 560 nm.

Viability assays
CellTiter Glo® luminescent assay kit from Promega
was used to assess cell viability. Cells were seeded in 96well plates at a density of 1X104 cells per well and treated
as indicated. Cell viability was assessed 24, 48 and 72 hours
after treatment, following the manufacturer’s protocol.

MATERIALS AND METHODS

Immunoblotting

Materials

Immunoblotting was performed using standard
procedures. Proteins were separated by SDS-PAGE.
Membranes were blocked with 5% non-fat milk in
Tris-buffered saline with Tween 20 (TBST) for 1 hour
at room temperature (RT), and immunoblotted with
primary antibodies in 5% BSA-TBST overnight at
4°C. Following washing with TBST buffer, membranes
were incubated with horseradish peroxidase-conjugated
secondary antibodies for 1 hour and then washed with
TBST. Membranes were developed using the ECL
chemiluminescent detection system (Amersham).

Primary antibodies used were anti-MET, antipMET, anti-EGFR, anti-pEGFR, anti-GAB1, anti-pGAB1,
anti-AKT, anti-pAKT, anti-pERK1/2, (Cell Signaling
Technology) and anti-β-actin (Sigma). The antibody arrays
used were Proteome Profiler Human Phospho-Receptor
Tyrosine Kinase (RTK) (ARY001B) and Phospho-Kinase
Array (ARY003B) kits from R&D Systems. Recombinant
HGF and pro-HGF were purchased from R&D Systems.
The MET kinase inhibitor, JNJ38877605 was purchased
from Selleck Chemicals (Selleckchem). HGF-specific and
nonspecific (NSP) siRNAs were purchased from Dharmacon.

Phosphokinase arrays

Cell culture
A549, WI38 and H1993 cells were obtained from
ATCC and EBC-1 cells were purchased from XenoTech,
KS. EBC-1, A549 and WI38 cells were maintained in
minimum essential medium (MEM) and H1993 cells
were cultured in RPMI medium. Growth media were
supplemented with 10% fetal bovine serum, L-glutamine
and antibiotics and cells were maintained under standard
cell culture conditions at 37°C and 5% CO2. Conditioned
medium from fibroblasts was prepared from 18Co
fibroblasts as reported before [36]. Briefly, fibroblasts
were maintained in complete medium until they reached
confluence. The presence of HGF in conditioned media
was confirmed by immunoblotting and by ELISA as
described before [36]. Confluent cultures were rinsed and
maintained in serum-free MEM medium for another 36
hours. Cell supernatants were collected, centrifuged and
used immediately or were aliquoted and stored at -80°C.

The phosphorylation profiles of kinases and their
protein substrates were determined using Proteome
Profiler Human Phospho-Receptor Tyrosine Kinase
(RTK) and Human Phospho-Kinase Array kits (R&D
Systems), following the manufacturers protocol. Serumstarved EBC-1 cells were treated with JNJ38877605
for 6h in the absence or presence of recombinant HGF.
Cells were rinsed with PBS and then solubilized with
lysis buffer at a concentration of 1X107 cells/mL. Array
membranes that had been spotted with capture antibodies
were blocked with blocking buffer and then incubated
with 300 μg of cell lysates overnight. Arrays were washed
to remove unbound proteins followed by incubation
with detection antibodies conjugated to horseradish
peroxidase. Phosphorylated proteins were detected using
chemiluminescent reagents and quantified using the Image
Quant LAS 4000 array analysis software (GE Healthcare
Life Sciences).

Transwell migration assay

HGF silencing

Cytoselect cell migration assay kit was purchased
from Cell Biolabs and the assay was performed according

EBC-1 cells were seeded in a 6-well plate DMEM
growth medium. Upon reaching 80-90% confluence,
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growth medium was changed to Opti-MEM and cells were
transfected with HGF-specific siRNA (Dharmacon) using
Lipofectamine 2000 (Invitrogen). Non-specific (NSP),
nontargeting siRNA (Dharmacon) was used as a negative
control. Both HGF and NSP siRNAs were delivered at a
final concentration of 25 nM. Growth medium was changed
to DMEM without antibiotics after overnight transfection.
HGF silencing was confirmed by immunoblotting.

7. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R,
Zakowski MF, Kris MG, Varmus H. Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated
with a second mutation in the EGFR kinase domain. PLoS
Med. 2005; 2:e73.
8. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L,
Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang
WC, Yu CJ, et al. MET amplification occurs with or without
T790M mutations in EGFR mutant lung tumors with
acquired resistance to gefitinib or erlotinib. Proc Natl Acad
Sci U S A. 2007; 104:20932-20937.

Statistical analyses
All experiments were repeated at least three times.
Results are expressed as the mean ± SEM as indicated.
Statistical analyses using two-tailed student’s t-test were
performed with the GraphPad Prism 5.0 software. p < 0.05
was considered statistically significant.

9. Camidge DR, Pao W, Sequist LV. Acquired resistance to
TKIs in solid tumours: learning from lung cancer. Nat Rev
Clin Oncol. 2014; 11:473-481.
10. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto
A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel
D, Hirsh V, Shepherd FA, Sequist LV, et al. Phase III
multinational, randomized, double-blind, placebo-controlled
study of tivantinib (ARQ 197) plus erlotinib versus erlotinib
alone in previously treated patients with locally advanced or
metastatic nonsquamous non-small-cell lung cancer. J Clin
Oncol. 2015; 33:2667-2674.
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